scholarly journals The Effect of Gonadotropin-Releasing Hormone Analogue on Final Adult Height in Children with Idiopathic Short Stature

2019 ◽  
Vol 28 (6) ◽  
pp. 509-516 ◽  
Author(s):  
Nahla Khawaja ◽  
Hala Owaineh ◽  
Anwar Batieha ◽  
Oraib Frahid ◽  
Mohammed EL-Khateeb ◽  
...  
Keyword(s):  
Short Stature ◽  
Adult Height ◽  
Gonadotropin Releasing Hormone ◽  
Idiopathic Short Stature ◽  
Hormone Analogue ◽  
Historical Cohort ◽  
Releasing Hormone ◽  
Final Adult Height ◽  
Gonadotropin Releasing Hormone Analogue ◽  
Height Gain

Objective: To assess final adult height (FAH) in children with short stature treated with gonadotropin-releasing hormone analogue (GnRHa). Methods: All patients with idiopathic short stature (ISS) with normally timed puberty and a Tanner stage between 2 and 3, who achieved their FAH between 2005 and 2015, were included in this clinical historical cohort study. Height gain, FAH, and mid-parental height of 28 children with ISS who received GnRHa treatment for 1.8 ± 1.0 years to delay their puberty were compared to 31 untreated children. Results: The FAHs of the treated and the untreated girls were 151.3 ± 5.1 and 146.8 ± 3.8 cm (p = 0.01), respectively. The FAHs of the treated and the untreated boys were 156.4 ± 4.7 and 152.3 ± 5.7 cm (p = 0.111), respectively. The height gain in the treated and the untreated girls was 1.6 ± 7.8 and –3.6 ± 5.7 cm (p = 0.036), respectively. Height gain in the treated and the untreated boys was –5.1 ± 13.6 and –11.5 ± 8.4 cm (p = 0.171), respectively. Conclusion: GnRHa therapy has a modest effect in improving FAH in adolescent females with ISS but not in boys.

Short-term effects of gonadotropin-releasing hormone analogue treatment on leptin, ghrelin and peptide YY in girls with central precocious puberty

2021 ◽  
Vol 34 (4) ◽  
pp. 479-484
Author(s):  
Piyathida Wijarn ◽  
Preamrudee Poomthavorn ◽  
Patcharin Khlairit ◽  
Sarunyu Pongratanakul ◽  
Laor Chailurkit ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Peptide Yy ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Hormone Analogue ◽  
Short Term ◽  
Serum Leptin ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Analogue ◽  
Before And After

Abstract Objectives To determine appetite-regulating hormone levels in girls with central precocious puberty (CPP) before and after 20 weeks of gonadotropin-releasing hormone analogue (GnRH-A) treatment. Methods Eighteen newly diagnosed CPP girls were enrolled. Body composition measured by bioelectrical impedance analysis and GnRH-A test were performed with fasting serum leptin, ghrelin and peptide YY (PYY) measurements at baseline (before) and after 20 weeks of GnRH-A treatment. Results Following GnRH-A treatment, all patients had prepubertal gonadotropin and estradiol levels. Mean (SD) fat mass index (FMI) was significantly increased from 4.5 (1.7) to 5.0 (1.8) kg/m2 after treatment. Also, median (IQR) serum leptin level was significantly increased from 6.9 (4.2–8.6) to 7.4 (5.3–13.1) ng/mL. FMI had a positive correlation with serum leptin level (r=0.64, p=0.004). In contrast, no significant changes of serum ghrelin and PYY levels were observed. Conclusions Decreased estrogen following short-term GnRH-A treatment in CPP girls may cause an increase in appetite and consequently an elevation of FMI. Increased serum leptin may be a result of having increased FMI secondary to an increase in appetite.

Sign in / Sign up

Export Citation Format

Share Document